Parathyroid Disorders. Группа авторов

2Touvier M, Deschasaux M, Montourcy M, Sutton A, Charnuax N, Kess-Guyot E, Fezeu LK, Latino-Martel P, Druesne-Pecollo N, Malvy D, Galan P, Hercberg S, Ezzedine K, Souberbielle JC: Interpretation of plasma PTH concentrations according to 25OHD status, gender, age, weight status, and calcium intake: importance of the reference values. J Clin Endocrinol Metab 2014;99:1196–1203.

      3Souberbielle JC, Cormier C, Kindermans C, Gao P, Cantor T, Forette F, Baulieu EE: Vitamin D status and redefining serum parathyroid hormone reference range. J Clin Endocrinol Metab 2001;86:3086–3090.

4Souberbielle JC, Fayol V, Sault C, Lawson-Body E, Kahan A, Cormier A: Assay-specific decision limits for two new automated parathyroid hormone and 25-hydroxyvitamin D assays. Clin Chem 2005;51:395–400.

5Harvey A, Hu M, Gupta M, Butler R, Mitchell J, Berber E, Siperstein A, Milas M: A new, vitamin D-based, multidimensional nomogram for the diagnosis of primary hyperparathyroidism. Endocr Pract 2012;18:124–131.

6Rajhbeharrysingh U, El Youssef J, Leon E, Lasarev MR, Klein R, Vanek C, Mattar S, Berber E, Siperstein A, Shindo M, Milas M: Expanding the net: the re-evaluation of the multidimensional nomogram calculating the upper limit of normal PTH (maxPTH) in the setting of secondary hyperparathyroidism and the development of the MultIdimensional Predictive Hyperparathyroid model (Mi-PTH). Surgery 2016;159:226–239.

7Lavryk OA, Siperstein AE: Use of calcium and parathyroid hormone nomogram to distinguish between atypical primary hyperparathyroidism and normal patients. World J Surg 2017;41:122–128.

8Cao S, Hu Y, Zhao Y, Su Z, Xu Z, Gao X, Liao Q, Zhao Y: A retrospective study of elevated post-operative parathormone in primary hyperparathyroid patients. Oncotarget 2017;8:101158–101164.

9Cusano NE, Maalouf NM, Wang PY, Zhang C, Cremers SC, Haney EM, Bauer DC, Orwoll ES, Bilezikian JP: Normocalcemic hyperparathyroidism and hypoparathyroidism in two community-based nonreferral populations. J Clin Endocrinol Metab 2013;98:2734–2741.

10Vignali E, Cetani F, Chiavistelli S, Meola A, Saponaro F, Centoni R, Cianferotti L, Marcocci C: Normocalcemic primary hyperparathyroidism: a survey in a small village of Southern Italy. Endocr Connect 2015;4:172–178.

11Lundgren E, Rastad J, Thrufjell E, Akerstrom G, Ljunghall S: Population-based screening for primary hyperparathyroidism with serum calcium and parathyroid hormone values in menopausal women. Surgery 1997;121:287–294.

12Garcia-Martin A, Reyes-Garcia R, Munoz-Torres M: Normocalcemic primary hyperparathyroidism: one-year follow-up in one hundred postmenopausal women. Endocrine 2012;42:764–766.

13Majid H, Khan AH, Riaz M, Karimi H, Talati J: Identifying parathyroid hormone disorders and their phenotypes through a bone health screening panel: it’s not simple vitamin D deficiency! Endocr Pract 2016;22:814–821.

14Rubin MR, Bilezikian JP, McMahon DJ, Jacobs T, Shane E, Siris E, Udesky J, Silverberg SJ: The natural history of primary hyperparathyroidism with or without parathyroid surgery after 15 years. J Clin Endocrinol Metab 2008;93:3462–3470.

15Ho C, Conner DA, Pollak MR, Ladd DJ, Kifor O, Warren HB, Brown EM, Seidman JG, Seidman CE: A mouse model of human familial hypocalciuric hypercalcemia and neonatal severe hyperparathyroidism. Nat Genet 1995;11:389–394.

16Mallya SM, Gallagher JJ, Wild YK, Kifor O, Costa-Guda J, Saucier K, Brown EM, Arnold A: Abnormal parathyroid cell proliferation precedes biochemical abnormalities in a mouse model of primary hyperparathyroidism. Mol Endocrinol 2005;19:2603–2609.

17Libutti SK, Crabtree JS, Lorang D, Burns AL, Mazzanti C, Hewitt SM, O’Connor S, Ward JM, Emmert-Buck MR, Remaley A, Miller M, Turner E, Alexander HR, Arnold A, Marx SJ, Collins FS, Spiegel AM: Parathyroid gland-specific deletion of the mouse Men1 gene results in parathyroid neoplasia and hypercalcemic hyperparathyroidism. Cancer Res 2003;63:8022–8028.

18Bilezikian JP, Silverberg SJ: Normocalcemic primary hyperparathyroidism. Arq Bras Endocrinol Metabol 2010;54:106–109.

19Bordier P, Ryckewart A, Gueris J, Rasmussen H: On the pathogenesis of the so-called idiopathic hypercalciuria. Am J Med 1977;63:398–409.

20Palmieri S, Eller-Vainicher C, Cairoli E, Morelli V, Zhukouskaya VV, Verga U, Filopanti M, Vicentini L, Ferrero S, Spada A, Chiodini I: Hypercalciuria may persist after successful parathyroid surgery and it is associated with parathyroid hyperplasia. J Clin Endocrinol Metab 2015;100:2734–2742.

21Maruani G, Hertig A, Paillard M, Houillier P: Normocalcemic primary hyperparathyroidism: evidence for a generalized target-tissue resistance to parathyroid hormone. J Clin Endocrinol Metab 2003;88:4641–4648.

22Balenga N, Azimzadeh P, Hogue JA, Staats PN, Shi Y, Koh J, Dressman H, Olson JA Jr: Orphan adhesion GPCR GPR64/ADGRG2 is overexpressed in parathyroid tumors and attenuates calcium-sensing receptor-mediated signaling. J Bone Miner Res 2017;32:654–666.

23Díaz-Soto G, Romero E, Castrillón JL, Jauregui OI, de Luis Román D: Clinical expression of calcium sensing receptor polymorphism (A986S) in normocalcemic and asymptomatic hyperparathyroidism. Horm Metab Res 2016;48:163–168.

24Díaz-Soto G, Romero E, Pérez-Castrillón JL, Jauregui OI, de Luis Román D: Parathyroid hormone polymorphism RS6254 is associated with the development and severity of osteoporosis in asymptomatic but not normocalcemic hyperthyroidism. Horm Metab Res 2016;48:828–833.

25Bilezikian JP, Brandi ML, Eastell R, Silverberg SJ, Udelsman R, Marcocci C, Potts JT Jr: Guidelines for the management of asymptomatic primary hyperparathyroidism: summary statement from the Fourth International Workshop. J Clin Endocrinol Metab 2014;99:3561–3569.

26Forster J, Monchik JM, Martin HF: A comparative study of serum ultrafiltrable, ionized, and total calcium in the diagnosis of primary hyperparathyroidism in patients with intermittent or no elevation in total calcium. Surgery 1998;104:1137–1142.

27Som M, Stroup JS: Primary hyperparathyroidism and pregnancy. Proc Bayl Univ Med Cent 2011;24:220–223.